UBS O'Connor’s Genmab GMAB Stock Holding History

UBS O'Connor’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-158,719	Closed	-$3.28M	–	351
2025 Q2	$3.28M	Buy	158,719 +86,842	+121%	+$1.78M	0.09%	103
2025 Q1	$1.41M	Buy	+71,877	New	+$1.51M	0.03%	154

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS O'Connor's GMAB Position: Q3 2025 in Review

UBS O'Connor sold out of Genmab (GMAB) in Q3 2025, closing a stake of 158,719 shares — an estimated $3.28M sold.

UBS O'Connor first reported a position in GMAB in Q1 2025 and held it in 2 quarters. The position peaked at $3.28M in Q2 2025. 253 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

UBS O'Connor reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
UBS O'Connor sold 158,719 Genmab shares in Q3 2025, an estimated $3.28M.
UBS O'Connor first reported a position in Genmab in Q1 2025 and held it in 2 quarters.
UBS O'Connor's Genmab position peaked at $3.28M in Q2 2025.
253 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.